Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
CONCLUSIONS: We found evidence for an optimal level of 25-D above which suppression of PTH progressively diminishes. This level is more than twice that currently recommended for the general population. We found no association between these higher 25-D levels and hyperphosphatemia or hypercalcemia. Additional prospective trials seem appropriate to test the idea that 25-D levels around 40-50 ng/ml could be a safe and effective treatment target for secondary hyperparathyroidism in CKD.
PMID: 25736620 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)
